Metformin and lung cancer

Metformin, a commonly used anti-diabetic drug has emerged as a potential anti-cancer drug. Over the last few years, a mass of epidemiologic, outcomes and preclinical data has emerged demonstratic the potential clinical relevance and the mechanistic basis of the anti-cancer activity of this well tolerated drug in lung cancer. This review article summarizes this evidence that supports the trial of this drug in in lung cancer.